Bufalin inhibits CYP3A4 activity in vitro and in vivo

Acta Pharmacologica Sinica

Volumn 30, Issue 5, 2009, Pages 646-652

  Li, Hai Yun ^a   Xu, Wen ^b   Zhang, Xi ^a   Zhang, Wei Dong ^a,c   Hu, Li Wei ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Bufalin; Cytochrome CYP3A4; Inhibitory interaction; Pharmacokinetics

Indexed keywords

BUFALIN; CYTOCHROME P450 3A4; MIDAZOLAM;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT;

ANIMALS; BUFANOLIDES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; DRUGS, CHINESE HERBAL; HUMANS; MALE; MIDAZOLAM; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECOMBINANT PROTEINS;

EID: 66749141095     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.42     Document Type: Article

References (25)

1. Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002; 30: 795-804.
2. Wang RW, Newton DJ, Liu N, Atkins WM, Lu AY. Human cytochrome P-450 3A4: in vitro drug drug interaction paterns are substrate-dependent. Drug Metab Dispos 2000; 28: 360-6.
3. Quintieri L, Palatini P, Nassi A, Ruzza P, Floreani M. Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP3A4 and CYP3A5 enzymes. Biochem Pharmacol 2008; 75: 1426 -37.
4. Casabar RC, Wallace AD, Hodgson E, Rose RL. Metabolism of endosulfan-α by human liver microsomes and its utility as a simultaneous in vitro probe for CYP2B6 and CYP3A4. Drug Metab Dispos 2006; 34: 1779-85.
5. Yetley E. Multivitamin and multimineral dietary supplements: defnitions, characterization, bioavailability, and drug interactions. Am J Clin Nutr 2007; 85: 269S-76S.
6. Bick RJ, Poindexter BJ, Sweney RR, Dasgupta A. Efects of Chan Su, a traditional Chinese medicine, on the calcium transients of isolated cardiomyocytes: cardiotoxicity due to more than Na, K-ATPase blocking. Life Sci 2002; 72: 699-709.
7. Nishikawa M, Ariyoshi N, Kotani A, Ishii I, Nakamura H, Nakasa H, et al. Efects of continuous ingestion of green tea or grape seed extracts on the pharmacokinetics of midazolam. Drug Metab Pharmacokinet 2004; 19: 280-9.
8. Shimazaki M, Martin J. Do herbal agents have a place in the treatment of sleep problems in long-term care? J Am Med Dir Assoc 2007; 8: 248-52.
9. Delgoda R, Westlake A. Herbal interactions involving cytochrome P450 enzymes. Toxicol Rev 2004; 23: 239-49.
10. Bhuiyana B, Fantb M, Dasgupta A. Study on mechanism of action of Chinese medicine Chan Su: dose dependent biphasic production of nitric oxide in trophoblastic BeWo cells. Clin Chim Acta 2003; 330: 179-84
11. Biddle DA, Datta P, Wells A, Dasgupta A. Falsely elevated serum digitoxin concentrations due to cross-reactivity of water-extractable digitoxin-like immunoreactivity of Chinese medicine Chan SU: elimination of interference by use of a chemiluminescent assay. Clin Chim Acta 2000; 300: 151-8.
12. Yin JQ, Shen JN, Su W W, Wang J, Huang G, Jin S, et al. Bufalin induces apoptosis in human osteosarcoma U-2OS and U-2OS methotrexate300- resistant cell lines. Acta Pharmacol Sin 2007; 28: 712-20.
13. l cell cycle arrest of endometriotic stromal cells: a promising agent for the treatment of endometriosis. Mol Hum Reprod 2005; 11: 8l7-23.
14. Zhang L, Nakaya K, Yoshida T, Kuroiwa Y. Induction by bufalin of diferentiation of human leukemia cells HL60 U937 and ML1 toward macrophage/monocyte-like cells and its potent synergistic efect on the diferentiation of human leukemia cells. Cancer Res 1992; 52: 4634-41.
15. Krenn L, Kopp B. Bufadienolides from animal and plant sources. Phytochemistry 1998; 48: 1-29.
16. Song H, Guo T, Bi K, Wang H, Zhang R. Determination of resibufogenin and cinobufagin in heart-protecting musk pill by HPLC. Biomed Chromatogr 2000; 14: 130-2.
17. Kawazoe N, Watabe M, Masuda Y, Nakaio S, Nakaya K. Tiam1 is involved in the regulation of bufalin-induced apoptosis in human leukemia cells. Oncogene 1999; 18: 2413-21.
18. Yeh JY, Huang WJ, Kan SF, Wang PS. Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate 2003; 54: 112-24.
19. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, et al. Characterization of interintestinal and intraintestinal diferences in human CYP3A-dependent metabolism. J Pharmacol Exp Ter 1997; 283: 1552-62.
20. Tateishi T, Watanabe M, Moriya H, Yamaguchi S, Sato T, Kobayashi S. No ethnic diference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. Biochem Pharmacol 1999; 57: 935-9.
21. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliver Rev 1997; 27: 201-14.
22. Hamaoka N, Oda Y, Hase I, Asada A. Cytochrome P4502B6 and 2C9 do not metabolize midazolam: kinetic analysis and inhibition study with monoclonal antibodies. Br J Anaesth 2001; 86: 540-4.
23. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62: 162-72.
24. Patki KC, Moltke LL, Greenblatt DJ. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: role of CYP3A4 and CYP3A5. Drug Metab Dispos 2003; 31: 938-44.
25. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999; 16: 408-14.